在癌症患者中,卡博桑提尼布与肝毒性相关的风险较高
Zhen Wang1, Lili Jiang1, Xin Lv1
1School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China.
Critical reviews in oncology/hematology
|February 16, 2024
概括
卡博桑提尼布增加了癌症患者肝损伤 (肝毒性) 的风险. 与其他癌症药物相比,这种氨酸激酶抑制剂显示肝酶升高的风险更高.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 卡博桑提尼布在各种固体瘤中表现出有效性.
- 肝毒性是针对性癌症治疗的一个重要问题.
- 评估卡博赞提尼布的肝毒性风险对于患者安全至关重要.
研究的目的:
- 在癌症患者中评估与cabozantinib相关的肝毒性风险.
- 为了比较卡博赞提尼布的肝毒性概况与其他癌症治疗方法.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了PubMed,Cochrane和EMBASE数据库,截至2023年9月9日.
- 分析了阿斯巴酸胺转移酶 (AST) 和氨酸胺转移酶 (ALT) 的所有级别和严重 (级别≥3) 的升高.
主要成果:
- 包括8个涉及2613名患者的RCT.
- 卡博桑提尼布显著增加了所有级别的AST和ALT升高的风险 (RR分别为2.63和2.89).
- 与对照组相比,卡博桑提尼布还增加了严重AST和ALT升高的风险 (RR分别为2.26和3.40).
- 亚组分析表明,卡博桑提尼布的肝毒性风险较高,而其它氨酸激酶抑制剂 (TKI) 和非TKI药物相比.
结论:
- 与其他固体瘤药物相比,卡博赞提尼布与肝毒性风险更高有关.
- 这包括与TKIs如erlotinib,sunitinib,sorafenib以及非TKIs如everolimus和paclitaxel的比较.
- 在治疗癌症患者时,临床医生应考虑cabozantinib的肝损伤潜力.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K


